Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELA study of BLU-222 in advanced solid tumors
2022-502528-29-00Phase 2Completed
- Sponsor
- Blueprint Medicines
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of BLU-222 in breast cancer, ovarian cancer, endometrial cancer (EC) and 2 more (3 arms), sponsored by Blueprint Medicines. Started Oct 2023; status: completed.
02
Drugs
BLU-222
03
Conditions
breast cancerovarian cancerendometrial cancer (EC)gastric cancer (GC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2022-502528-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502528-29-00.